Imfinzi improved OS & PFS in limited-stage SCLC
05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca's Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small